<DOC>
	<DOCNO>NCT01875601</DOCNO>
	<brief_summary>BACKGROUND : - Despite progress , child young adult solid tumor still experience poor survival . - Activated NK cell potently kill autologous pediatric solid tumor , clinical grade procedure available generate large number activate NK cell adoptive cell therapy . OBJECTIVES : - Primary objective : 1 ) ass feasibility harvest expand activate NK cell meet escalate dose goal Cohort A , 2 ) ass toxicity infuse escalate dos activate NK cell follow lymphodepleting chemotherapy without rhIL15 ( cohort A ) , 3 ) ass toxicity infuse NK activate cell escalate dos rhIL15 ( cohort B ) pediatric patient refractory malignant solid tumor . - Secondary objective : 1 ) identify biologically active dos activate autologous NK cell plus minus rhIL15 monitoring change NK cell number , phenotype function , 2 ) ass pharmacokinetics immunogenicity rhIL15 pediatric population , 3 ) ass antitumor effect change FDG-PET follow administration activate NK cell lymphopenic host plus minus rhIL15 . 4 ) evaluate saftey efficacy subsequent cycle autologous NK cell infusion patient cohort A received benefit first NK cell infusion . ELIGIBILITY : - Patients Cohort A : 2-29 year refractory pediatric malignant solid tumor , Patients Cohort B : 2-25 year refractory pediatric malignant solid tumor . - Adequate performance status organ function , recover toxic effect prior therapy , requirement systemic corticosteroid history allogeneic stem cell transplantation . DESIGN : - All patient receive pre-NK lymphodepleting chemotherapy cyclophosphamide . - Cohort A receives escalate dos activate autologous NK cell identify feasibility generate cell tolerability , potentially identify MTD . - A1 : 1x10 ( 6 ) NK cells/kg - A2 : 1 x 10 ( 7 ) NK cells/kg - A3 : 1 x 10 ( 8 ) NK cells/kg - If feasibility acceptable toxicity demonstrate dos Cohort A , patient enrol cohort B receive activate autologous NK cell plus escalate dos rhIL15 use follow schema : - B1 : 1 x 10 ( 7 ) NK cells/kg + rhIL15 0.25 mcg/kg/d IV x 10 - B2 : 1 x 10 ( 7 ) NK cells/kg + rhIL15 0.25 mcg/kg/d IV x 10 - B3 : 1 x 10 ( 7 ) NK cells/kg + rhIL15 0.5 mcg/kg/d IV x 10 - B4 : 1 x 10 ( 7 ) NK cells/kg + rhIL15 0.75 mcg/kg/d IV x 10 - Three patient enrol dose level , dose level expand 6 dose-limiting toxicity occur . An expand group 12 patient treated high tolerable dose level . DLT toxicity monitoring continue 21 day NK infusion , 14 day last rhIL15 dose Cohort B ( whichever later ) .</brief_summary>
	<brief_title>NK White Blood Cells Interleukin Children Young Adults With Advanced Solid Tumors</brief_title>
	<detailed_description>BACKGROUND : - Despite progress , child young adult solid tumor still experience poor survival . - Activated NK cell potently kill autologous pediatric solid tumor , clinical grade procedure available generate large number activate NK cell adoptive cell therapy . OBJECTIVES : - Primary objective : 1 ) ass feasibility harvest expand activate NK cell meet escalate dose goal Cohort A , 2 ) ass toxicity infuse escalate dos activate NK cell follow lymphodepleting chemotherapy without rhIL15 ( cohort A ) , 3 ) ass toxicity infuse NK activate cell escalate dos rhIL15 ( cohort B ) pediatric patient refractory malignant solid tumor . - Secondary objective : 1 ) identify biologically active dos activate autologous NK cell plus minus rhIL15 monitoring change NK cell number , phenotype function , 2 ) ass pharmacokinetics immunogenicity rhIL15 pediatric population , 3 ) ass antitumor effect change FDG-PET follow administration activate NK cell lymphopenic host plus minus rhIL15 . 4 ) evaluate saftey efficacy subsequent cycle autologous NK cell infusion patient cohort A received benefit first NK cell infusion . ELIGIBILITY : - Patients Cohort A : 2-29 year refractory pediatric malignant solid tumor , Patients Cohort B : 2-25 year refractory pediatric malignant solid tumor . - Adequate performance status organ function , recover toxic effect prior therapy , requirement systemic corticosteroid history allogeneic stem cell transplantation . DESIGN : - All patient receive pre-NK lymphodepleting chemotherapy cyclophosphamide . - Cohort A receives escalate dos activate autologous NK cell identify feasibility generate cell tolerability , potentially identify MTD . - A1 : 1x10 ( 6 ) NK cells/kg - A2 : 1 x 10 ( 7 ) NK cells/kg - A3 : 1 x 10 ( 8 ) NK cells/kg - If feasibility acceptable toxicity demonstrate dos Cohort A , patient enrol cohort B receive activate autologous NK cell plus escalate dos rhIL15 use follow schema : - B1 : 1 x 10 ( 7 ) NK cells/kg + rhIL15 0.25 mcg/kg/d IV x 10 - B2 : 1 x 10 ( 7 ) NK cells/kg + rhIL15 0.25 mcg/kg/d IV x 10 - B3 : 1 x 10 ( 7 ) NK cells/kg + rhIL15 0.5 mcg/kg/d IV x 10 - B4 : 1 x 10 ( 7 ) NK cells/kg + rhIL15 0.75 mcg/kg/d IV x 10 - Three patient enrol dose level , dose level expand 6 dose-limiting toxicity occur . An expand group 12 patient treated high tolerable dose level . DLT toxicity monitoring continue 21 day NK infusion , 14 day last rhIL15 dose Cohort B ( whichever later ) .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<criteria>INCLUSION CRITERIA : Diagnosis : Histologically confirm solid tumor , include primary brain tumor . In subject brain stem optic glioma requirement histological confirmation may waive . Age : Cohort A : 2 less equal 29 year old time enrollment . Cohort B : 2 less equal 25 year old time enrollment . Patients must evaluable measurable malignant disease enrollment . Prior Therapy : The patient malignancy must relapse failed respond frontline curative therapy and/or must potentially curative treatment option available time study entry . There limit number prior treatment regimen . However , patient must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior study enrollment . Acute toxicity previous therapy must resolve grade 1 less , unless specify elsewhere . Myelosuppressive chemotherapy : Patients must receive myelosuppressive chemotherapy within 3 week enrollment ( 6 week prior nitrosourea ) . Hematopoietic growth factor : At least 7 day must elapse since completion therapy growth factor . At least 14 day must elapse receive pegfilgrastim . Biologic ( antineoplastic agent ) metronomic nonmyelosuppressive chemotherapy : At least 7 day must elapse since completion therapy biologic agent . For agent know adverse event occur beyond 7 day administration , period prior enrollment must extend beyond time adverse event know occur . Monoclonal antibody : At least 4 week must elapse since prior therapy include monoclonal antibody . Radiotherapy : 3 week must elapse since XRT Performance status : ECOG 0 , 1 2 , child less equal to10 year age , Lansky great equal 60 . Note : Patients unable walk paralysis , wheelchair , consider ambulatory purpose assess performance score . Cardiac function : Left ventricular ejection fraction great equal 45 % fractional shortening great equal to28 % . Liver function : Serum total bilirubin &lt; 2 mg/dl , serum AST ALT less equal 3 x upper limit normal . Patients Gilbert syndrome exclude requirement normal bilirubin . ( Gilbert syndrome find 310 % general population , characterize mild , chronic unconjugated hyperbilirubinemia absence liver disease overt hemolysis ) . On cohort B , patient liver involvement tumor eligible due potential confounding risk hepatotoxicity rhIL15 administer . NOTE : adult value use calculate hepatic toxicity trial , standard POB phase I trials . Renal function : Ageadjusted normal serum creatinine accord follow table creatinine clearance great equal 60 ml/min/1.73 ( 2 ) . Age ( year ) &lt; TAB &gt; &lt; TAB &gt; &lt; TAB &gt; Maximum serum creatinine ( mg/dl ) less equal to5 &lt; TAB &gt; &lt; TAB &gt; 0.8 &gt; 5 less equal 10 &lt; TAB &gt; 1.0 &gt; 10 less equal 15 &lt; TAB &gt; 1.2 &gt; 15 &lt; TAB &gt; &lt; TAB &gt; &lt; TAB &gt; &lt; TAB &gt; 1.5 Marrow function : ANC must &gt; 750/mm ( 3 ) ( unless due underlie disease case grade restriction ) , platelet count must great equal 75,000/mm ( 3 ) ( achieve transfusion ) . Lymphopenia , CD4 lymphopenia , leukopenia , anemia render patient ineligible . Female patient ( relevant male partner ) must willing practice birth control ( include abstinence ) two month treatment , childbearing potential . Ability give inform consent . For patient &lt; 18 year age legal guardian must give informed consent . Pediatric patient include ageappropriate discussion order obtain verbal assent . Durable power attorney form offer ( patient great equal to18 year age ) . EXCLUSION CRITERIA : Untreated CNS metastatic disease define : Solid Tumors : History untreated metastatic CNS tumor involvement . Extradural mass invade brain parenchyma parameningeal tumor without evidence leptomeningeal spread render patient ineligible . Patients previous CNS tumor involvement eligible IF CNS tumor ( ) treat stable resolve least 4 week ; patient currently require steroid . Prior history allogeneic stem cell transplantation . Breast feed pregnant female ( due risk fetus newborn ) . HIV HTLVI/II ( due unacceptable risk associate severe immune suppression risk associate cell product ) . Hepatitis B surface antigen ( HBsAg ) positive hepatitis C antibody positive elevate liver transaminase . All patient chronic active hepatitis ( include antiviral therapy ) ineligible . Patients require systemic corticosteroid systemic immunosuppressive therapy . Immunosuppressive therapy must stop least 28 day prior enrollment . Topical agent and/or inhaled corticosteroid permit . High risk inability comply therapy estimation PI . Clinically significant systemic illness ( e.g . serious active infection significant vital organ dysfunction ) , judgment PI would likely compromise patient ability tolerate protocol therapy significantly increase risk complication . Prior history pericarditis pericardial effusion . INCLUSION OF WOMEN AND MINORITIES : Both men woman race ethnic group eligible trial .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>October 27, 2016</verification_date>
	<keyword>NK Cells</keyword>
	<keyword>Cytokine</keyword>
	<keyword>Lymphodepleting Chemotherapy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Pediatric</keyword>
</DOC>